MedTrace Logo

mtDNA as Novel Biomarker for Intra-amniotic Infection

NCT03306719 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2017-10-11

No results posted yet for this study

Summary

Finding a predictive biomarker for IAI could improve the clinical outcome for the mother and the neonate. The aim of this study is to quantify the copy number of circulating cell-free mitochondrial DNA in maternal serum and the placenta compared to controls.the investigators hypothesise that circulating cell-free mitochondrial DNA levels could help predict the likelihood of early inflammation in IAI. In addition, mitochondrial DNA could be a promotor triggering the pathogenesis of systemic inflammation.

Conditions

  • Preterm Premature Rupture of Membrane

Interventions

BIOLOGICAL

Blood sampling

Serial blood sampling

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Herbert Kiss, MD, PhD · Medical University of Vienna

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-05
Primary Completion
2018-06-30
Completion
2018-12-31

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03306719 on ClinicalTrials.gov